StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 7, 2026, 04:27 PM

Alector Q1 Net Loss Narrows 43% to $(22.9)M; Expenses Down

AI Summary

Alector, Inc. reported a significant reduction in its net loss for the first quarter of 2026, narrowing to $(22.9) million from $(40.5) million in the prior year period. This improvement was primarily driven by substantial decreases in both research and development and general and administrative expenses, which were influenced by prior workforce reductions. However, collaboration revenue saw a notable decline, and the company's cash and marketable securities decreased compared to the end of 2025.

Key Highlights

  • Net loss narrowed by 43.3% to $(22.9) million in Q1 2026 from $(40.5) million in Q1 2025.
  • Research and development expenses decreased by 46.9% to $17.9 million in Q1 2026.
  • General and administrative expenses decreased by 44.9% to $8.1 million in Q1 2026.
  • Collaboration revenue decreased by 71.5% to $1.0 million in Q1 2026.
  • Cash, cash equivalents, and marketable securities totaled $206.5 million as of March 31, 2026.
  • Total assets decreased to $239.9 million as of March 31, 2026 from $293.2 million.
  • Workforce reductions included 47% in October 2025 and 13% in March 2025.